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Recent studies have shown the public health importance of identifying individuals with acute human
immunodeficiency virus infection (AHI); however, the cost of nucleic acid amplification testing (NAAT) makes
individual testing of at-risk individuals prohibitively expensive in many settings. Pooled NAAT (or group
testing) can improve efficiency and test performance of testing for AHI, but optimizing the pooling algorithm
can be difficult. We developed simple, flexible biostatistical models of specimen pooling with NAAT for the
identification of AHI cases; these models incorporate group testing theory, operating characteristics of bio-
logical assays, and a model of viral dynamics during AHI. Pooling algorithm sensitivity, efficiency (test kits
used per individual specimen evaluated), and positive predictive value (PPV) were modeled and compared for
three simple pooling algorithms: two-stage minipools (D2), three-stage hierarchical pools (D3), and square
arrays with master pools (A2m). We confirmed the results by stochastic simulation and produced reference
tables and a Web calculator to facilitate pooling by investigators without specific biostatistical expertise. All
three pooling strategies demonstrated improved efficiency and PPV for AHI case detection compared to
individual NAAT. D3 and A2m algorithms generally provided better efficiency and PPV than D2; additionally,
A2m generally exhibited better PPV than D3. Used selectively and carefully, the simple models developed here
can guide the selection of a pooling algorithm for the detection of AHI cases in a wide variety of settings.
Nucleic acid amplification testing (NAAT) has revolution-
ized testing for infectious diseases (17), but the technique
remains expensive (6, 9, 27) and exhibits poor predictive value
in many settings. In the last decade, laboratories have turned to
specimen pooling or group testing strategies to increase both
the efficiency and the predictive value of NAAT for use in
screening for rare diseases (23, 24, 27, 31). In group testing,
biological specimens are pooled together, and these pools
(rather than the individual specimens) are initially tested. If a
pool tests positive, further testing is required to identify indi-
vidual positive specimens; however, if the pool tests negative,
all specimens in that pool are declared negative. Thus, group
testing can lead to a decrease in the average number of tests
required per specimen evaluated compared to individual test-
ing. Group testing can also lead to higher specificity and thus
to higher positive predictive values in a screening setting.
The idea of group testing to increase the efficiency of case
detection was popularized by Dorfman (5), whose work was
motivated by syphilis screening in military inductees. Subse-
quently, group testing techniques have been applied to other
infectious viruses, including human immunodeficiency virus
(HIV) (1, 23, 24, 31), hepatitis B and C viruses (23), and West
Nile virus (3). Group testing has also found broader applica-
tion in blood banks (23, 25), entomology (34), genetics (11),
pharmaceuticals (14), analytical chemistry (37), and informa-
tion theory (36). More recently, a number of public health
laboratories in the United States (18, 27, 28, 30, 32) and else-
where (4, 10, 29, 33) have adopted new clinical HIV testing
algorithms that incorporate specimen pooling with NAAT to
identify acute HIV infection (AHI) in the period before HIV
antibodies develop.
As group testing has been applied in a wide variety of fields,
extensions of Dorfman’s original “minipool” algorithm (5)
(Fig. 1a) have been proposed. For example, Finucan (8) ex-
tended Dorfman’s minipools to a three-stage, hierarchical con-
figuration (Fig. 1b). More recently, Phatarfod and Sudbury
(26) and others (2, 15, 16, 37) have proposed array-based
pooling strategies (Fig. 1c).
Properties of these different group testing algorithms have
been reported extensively in the biostatistics literature. For
example, if the prevalence of disease p is known and there is no
test error (i.e., 100% sensitivity and specificity), then the opti-
mally efficient size of the master pool (i.e., the first and largest
pool tested in a pooling algorithm) is known to be approxi-
mately p1/2 for Dorfman minipools, and p2/3 for three-stage
hierarchical pools (8). Closed-form solutions of the operating
characteristics for many pooling strategies have been derived.
These results enable the examination of various levels of prev-
alence, sensitivity, and specificity on the efficiency and positive
predictive value (PPV) of group testing algorithms (11, 15, 16,
22). However, much of this work has been highly technical and
too theoretical to be directly useful to the laboratory directors
and technicians most likely to implement pooled testing for
AHI in clinical or public health settings. Likewise, no formal
investigation of which strategies might be best for case detec-
tion of AHI has been undertaken.
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Our goals in this paper were therefore to (i) develop simple,
flexible models of group testing for NAAT-based AHI case
detection, incorporating explicit assumptions about viral dy-
namics during AHI and known operating characteristics of
enzyme-linked immunosorbent assays (ELISAs) for antibodies
and NAATs; (ii) employ these models to compare levels of
pooling algorithm sensitivity (PAS), efficiency, and PPVs of
different pooling strategies for detection of AHI; and (iii)
demonstrate how these models can guide pooling algorithm
selection in real-world applications (4, 10, 27–29, 33).
MATERIALS AND METHODS
Decision-making framework. Models were developed to determine the best
pooling strategy for a given testing situation. Four questions were identified as
key to this process. (i) What practical considerations restrict the pooling strate-
gies available to the laboratory? (ii) How do pool size and the choice of assay for
NAAT affect the ability of a pooling algorithm to detect patients with AHI in a
testing population? (ii) Given the assay and maximum pool size, what efficiencies
can be expected for different pooling strategies in testing populations with dif-
ferent prevalences of AHI? (iv) How can pooling strategies be expected to
impact the accuracy of NAAT results, in terms of the PPV?
The first question, addressed in the Discussion, considers throughput (number
of samples to be processed per unit time), desired turnaround time, and available
resources (budget, technology, personnel, assays) and frames the range of strat-
egies a laboratory can consider for a real-world application. The three remaining
questions were addressed using appropriate statistical models as described be-
low.
Group testing strategies examined. We examined the three testing strategies
shown in Fig. 1. The first was the two-stage Dorfman minipool strategy (or “D2”)
(5). In the first stage of D2, the master pool comprising all specimens is tested;
if the master pool tests positive, all component individual specimens are tested
(the second of the two stages). The second strategy was an extension of D2 into
a three-stage hierarchical form (“D3”) (8, 13), in which a master pool is first
tested; if the master pool tests positive, then the component subpools are tested.
Last, the individual specimens which comprise each positive subpool are tested.
Only “square” D3 pools were examined (e.g., a master pool of 25 comprising 5
subpools of 5 specimens each), as this configuration of D3 is approximately
optimal in the absence of test error (8). The third pooling strategy was a two-
dimensional array (“A2m”) with master pool testing (15, 16). As in D2 and D3,
the master pool is tested in the first stage of A2m; if the master pool tests
positive, then pools comprising all specimens of each row and each column of the
array are tested simultaneously. All specimens at points of intersection between
positive rows and positive columns are then retested. In the event of a positive
row but no positive columns (or vice versa), all specimens in the positive row are
tested. Since testing row and column pools occurs in a single step of the testing
process, A2m (like D3) is a three-stage pooling algorithm. Only A2m algorithms
with an equal number of rows and columns were considered.
Defining AHI prevalence. In most published examples of specimen pooling to
identify AHI (10, 27–29, 32), individual specimens were first screened for chronic
HIV infection using an ELISA for antibodies; ELISA-negative specimens were
then pooled and tested using HIV NAAT for the presence of virus. We therefore
defined AHI prevalence as the proportion of antibody-negative individuals in the
population of interest who would individually test positive by NAAT. By defini-
tion, prevalent AHI cases fall within a time window bounded by the date at which
an individual would first test positive by NAAT and the date at which that
individual would first test positive by ELISA. The expected length of this sensi-
tivity window (w) (i.e., the expected number of days between NAAT positivity
and seroconversion) depends on the particular ELISA and NAAT being em-
ployed (19, 35). Given a NAAT with a lower limit of detection (LLD) of 100
copies/ml, Fiebig et al. (7) estimated that w would be 84 days (95% confidence
interval [CI], 42 to 125) for a second-generation ELISA, 9 days (95% CI, 5 to 12)
for a third-generation ELISA, and 5 (95% CI, 2 to 9) for a fourth-generation
ELISA (which includes antigen as well as antibody testing).
Modeling PAS. While the maximum acceptable pool size (MAPS) for a pool-
ing application is driven in part by logistical considerations (see Discussion),
pooling almost always results in the loss of sensitivity compared to individual
testing. Thus, bounding pool size may also be necessary to limit loss of sensitivity.
We defined pooling algorithm sensitivity (PAS) as the probability that a truly
positive specimen will be declared positive by a particular pooling algorithm, and
assay sensitivity as the probability that a truly positive specimen will be declared
positive by an individual NAAT. PAS was modeled as a function of assay
sensitivity under the following assumptions. (i) AHI cases present uniformly
throughout the sensitivity window period. (ii) During the first weeks of AHI, an
individual’s viral load rapidly increases from being undetectable to very high
levels (107 copies/ml) at a constant exponential rate R (7); thereafter, HIV
remains detectable by any available NAAT. (iii) The probability a pool is de-
clared positive is a deterministic function of the amount of virus in the pool. (iv)
PAS is affected by dilution only in the first stage of a pooling algorithm. As-
sumption iv is based on the intuition that viral load will increase in subpools
FIG. 1. Schematic diagrams of three pooled testing strategies considered: D2, D3, and A2m. Positive pools are in gray; positive specimens are
in black. In D2 (a), a positive master pool is broken down into individual specimens. One or more of these specimens may be positive. In D3 (b),
a positive master pool is broken down into multiple subpools, all of which are tested. Positive subpools are broken into individual specimens, and
one or more of these specimens may be positive. In A2m (c), if a master pool is positive, row and column pools are tested, some of which may
be positive. Specimens at the intersection of positive row and column pools are tested individually; some or all of these may be positive.
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compared to positive master pools due to decreased dilution. Thus, if a master
pool correctly tests positive, one would expect at least one subpool to also test
positive. This expectation is in line with laboratory experience in North Carolina
(27, 28), Seattle (32), and South Africa (33), where positive master pools have
rarely failed to give rise to at least one positive subpool.
Modeling pooling efficiency and PPV. Efficiency of a pooling algorithm was
defined as the expected number of NAATs required per individual specimen
evaluated, ignoring confirmatory retesting of individual positive specimens. Thus,
the efficiency of individual testing is 1, and an efficiency of less than 1 indicates
that the pooling algorithm will require fewer tests on average than individual
testing. The PPV of a pooling algorithm (henceforth, simply PPV) was defined as
the probability that a specimen identified as positive at the end of a pooling
algorithm was in fact truly positive (again, ignoring confirmatory retesting).
Pooling efficiency and PPV for D2, D3, and A2m were modeled using formulae
adapted from the group testing literature. These calculations require specifica-
tion of PAS, of AHI prevalence, and of assay specificity, which is the probability
that a truly negative specimen will be declared negative by an individual NAAT.
These models assume that assay specificity is not affected by pool size and that
specimens are independent and identically distributed with the probability of
being positive equal to a known AHI prevalence p in the population. Predictions
of these deterministic formulae were confirmed with stochastic simulations.
RESULTS
Relationship between pool size, assay sensitivity, and PAS.
Based on the model assumptions above, PAS is equivalent to
the proportion of days of the sensitivity window during which
positive specimens would be detectable in a master pool (ac-
counting for dilution). Given w, R (measured in log10 copies/
ml/day increase), and the size of the master pool N, it follows
that
PAS  1  log10 N/Rw (1)
When we solve equation 1 for N, we get:
N  10Rw1  PAS (2)
Therefore, MAPS must be less than or equal to N given in
equation 2 in order to achieve a sensitivity of at least PAS.
For a particular ELISA, there exists a one-to-one correspon-
dence between w and the LLD of NAAT. For instance, sup-
pose a particular NAAT has a known LLD and w (e.g., Fiebig
et al. [32] report an LLD of 100 copies/ml and a w of 9 when
used with a third-generation ELISA [32]). Then a different
NAAT with a different LLD (LLD) has a w as follows:
w  w  log10LLD/LLD/R (3)
Figure 2 was produced by combining equations 1 and 3, and it
shows PAS as a function of N with an R value of 0.52 log10
copies/ml/day (i.e., a doubling time of 	14 h) (7, 21) for
NAATs with various LLDs, assuming the samples were first
screened (and found negative) with a third-generation ELISA
(7). In Fig. 2, increases in pool size from 16 to 100 reduced the
likelihood of AHI detection by 15 to 30 percent. In practice,
effects of relatively large increases in pool size on PAS might
be offset by choosing a NAAT with a lower LLD.
Pooling efficiency and PPV. Formulae for pooling efficiency
and PPV for D2, D3, and A2m are given in the supplemental
material. For purposes of comparing the predicted perfor-
mance of pooling algorithms across a range of plausible AHI
prevalences (4, 10, 18, 27–30, 32, 33), assay specificities, and
PAS values, estimated values for efficiency and PPV for opti-
mally efficient algorithms are shown in Table 1 and Tables S1,
S2, and S3 in the supplemental material. Separate tables were
generated for different MAPS values; each table displays the
optimally efficient master pool size for the given MAPS, with
the corresponding efficiency and PPV. In addition, a Web
calculator which can produce the results presented in the ta-
bles is available at the website of M.G.H. (http://www.bios.unc
.edu/	mhudgens/optimal.pooling.htm).
Figure 3 shows graphs of the optimal efficiency for D2, D3,
and A2m over a range of AHI prevalences, specificities, and
PAS values. Figure 3 also shows the “entropy value” (2), the
theoretical best possible efficiency that can be achieved using
any group testing algorithm for a given prevalence. All three
pooling strategies greatly increase testing efficiency, often re-
sulting in 10-fold or greater reductions in test usage compared
to individual testing. Gains in efficiency due to pooling are
substantially better at lower prevalences. For the entire range
FIG. 2. Model of PAS as a function of master pool size (N) for hypothetical NAATs with different lower limits of detection. The model assumes
use of a third-generation ELISA and a rate of exponential increase of HIV viral load during early AHI of 0.52 log10 copies/ml/day.
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of prevalences considered, D3 and A2m have comparable ef-
ficiencies and are each more efficient than D2, though this gap
narrows considerably at higher AHI prevalences. Reductions
in assay specificity (center and left panels of Fig. 3) reduce the
testing efficiency of D2 algorithms; the efficiencies of D3 and
A2m are more robust with changes in assay specificity.
Figure 4 shows the PPV for the optimally efficient algo-
rithms considered in Fig. 3, along with the PPV of individual
testing. The results indicate that D3 and A2m algorithms will
in general confer meaningfully greater PPVs than will D2. In
addition, the figure shows many situations in which the PPV of
A2m is superior to that of D3. For instance, at AHI preva-
lences similar to those observed in North Carolina (p  2 

104) (27, 28), A2m algorithms should result in clinically sig-
nificant gains in PPV compared to D3 algorithms. The advan-
tage of the A2m algorithm is most striking where the assay
specificity is reduced. All three pooling strategies result in
substantial increases in PPV compared to individual NAAT
results.
DISCUSSION
Group testing for AHI case detection clearly offers substan-
tial advantages in both efficiency and PPV compared to indi-
vidual NAAT. The specific choice of pooling strategy can
meaningfully affect these factors and can also affect PAS. By
characterizing the relationships between pooling algorithm
performance, AHI prevalence in the testing population, and
NAAT performance characteristics, we have derived models to
guide laboratories interested in pooling for detection of AHI.
The efficiency and accuracy of all group testing strategies
depend on the prevalence of AHI as well as on the specificity
and sensitivity of the NAAT. In general, optimal master pool
sizes decrease as AHI prevalence increases. D3 appeared to
best optimize pooling efficiency over the widest range of preva-
lences among algorithms considered here. However, A2m
pools often showed comparable efficiency and better PPV than
D3 with imperfect assay specificity (Fig. 3 and 4). Where effi-
ciencies are comparable, then, A2m may provide a more robust
approach for case identification applications of pooling.
In contrast, the D2 algorithm is the simplest to execute and
(as a two-stage algorithm) has the benefit of reducing turn-
around time for reporting positive results compared to D3 or
A2m; perhaps for these reasons, D2 has been used widely by
blood banks (23, 25). However, D2 testing is generally less
efficient than D3 or A2m, except where the prevalence of AHI
is high. Moreover, the performance of D2 is markedly suscep-
tible to reduced specificity: even with small master pool sizes
(for example, 25 specimens), the presence of an occasional
false-positive NAAT affects the efficiency and PPV of D2 to a
much greater extent than comparable D3 or A2m pools at
most AHI prevalences (Table S3 in the supplemental mate-
rial). This effect is due to increased serial retesting of speci-
mens in D3 and A2m compared to D2. D2 should therefore be
considered only where there is high confidence in both assay
specificity and laboratory quality assurance.
A crucial concern in pooling is the loss of NAAT sensitivity
due to dilution of positive specimens in pools of increasing
size. For instance, Fig. 2 shows that, for a fixed w and R,
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in sensitivity to detect AHI cases; however, these results also
show that a very sensitive NAAT can partially offset this dilu-
tion effect. Even where pooling large numbers of specimens is
possible (i.e., in high-throughput laboratories or retrospective
research studies), the best AHI detection strategy ultimately
requires both a sensitive NAAT and limited master pool size.
The results of this study may prove useful in planning real-
world pooling programs. Preliminary considerations in this
FIG. 3. Optimal pooling efficiency for a range of prevalences assuming a MAPS of 100, by pooling strategy. Efficiency is measured as tests per
screened specimen. The figure shows the “entropy value” for efficiency, the theoretical best efficiency possible with any pooling algorithm.
FIG. 4. Pooling PPV for pooling configuration that achieves best possible efficiency, with a maximum acceptable pooling size (MAPS) of 100, for a range
of prevalences by pooling strategy. These PPVs correspond exactly to the efficiency graphs in Fig. 3. Also shown is the PPV for individual testing.
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planning process, summarized in Table 2, should include as-
sessment of (i) the laboratory setting, (ii) end-user require-
ments, and (iii) characteristics of the testing population.
Laboratory setting. Planners should consider the available
technology and quality assurance when implementing pooling.
While manual pooling of specimens is technologically simple
and feasible in low-resource settings (10, 29), the process is
labor intensive and requires extreme care with specimen han-
dling, rigorous quality control, and ongoing quality assurance.
However, our experiences in North Carolina and China have
been that whenever we find a positive pool, we are always able
to identify the sample or samples that made the pool positive.
While the serial retesting of specimen pooling algorithms re-
duces the impact of “pure” (noncontamination) false positives
on the overall PPV, a contaminated primary specimen may be
indistinguishable from a truly positive specimen. Moreover,
D2, D3, and A2m strategies potentially require increasing
numbers of samples to be drawn from each primary sample
tube (2, 3, and 4 samples, respectively), thus increasing the risk
of contamination. The availability of robotics may therefore be
a prerequisite for using A2m, as well as for using larger pool
sizes (in our experience, those greater than 50), where the risk
of contamination is also increased. Before settling on a final
choice, planners must also determine the level of testing effi-
ciency necessary given available resources; how many runs may
be performed per week given available personnel; what is
known about the cost, sensitivity, and specificity for the assays
available to the lab; and how many freeze-thaw cycles will be
necessary for a pooling algorithm, as the sensitivity of NAAT
may be reduced when stored samples undergo more than three
or four freeze-thaw cycles (20).
End-user requirements. Different end-user applications may
have different needs with regard to turnaround time (e.g.,
consider a retrospective study using stored samples compared
to a blood bank). For the three algorithms considered, negative
results can be returned after a single stage of testing, while
positive results require two (D2) or three (D3, A2m) stages.
End users will also have different requirements in terms of
accuracy. Researchers with time and resources to perform con-
firmatory tests might be less concerned with the PPV of an
algorithm than public health authorities who plan to intervene
immediately upon identifying an AHI case.
Testing population. The expected throughput can limit pos-
sible pool size and should therefore be known in advance. Labs
must accumulate enough specimens to complete master pools
before testing these pools; if specimens are slow in coming, the
lab may face the choice of delaying scheduled runs or wasting
resources by running assays with suboptimal numbers of spec-
imens. Some knowledge of the expected AHI prevalence in the
testing population is likewise required to estimate pooling al-
gorithm efficiency and accuracy and, in turn, to select an ap-
proximately optimal pooling configuration.
Once the foregoing assessment has been completed, many
planners will decide to limit the MAPS for their pooling ap-
plication. For this reason, Table 1 and Tables S1, S2, and S3 in
the supplemental material have been organized into four parts
by MAPS (values of 100, 225, 49, and 25, respectively). Opti-
mal pooling algorithms for any value of MAPS may also be
determined through use of the Web calculator.
This research has several important limitations. First, model
predictions may be deceptively precise, obscuring inherent un-
certainty and variation in the distribution and prevalence of
positive samples in the testing population; for instance, AHI
prevalence will rarely fall usefully on a power of ten, as in
Table 1. For these reasons, model predictions should be con-
sidered approximate. An iterative or “sensitivity analysis” ap-
proach to finding the best pooling algorithm may be warranted
in many situations. For instance, the investigator can assess the
robustness of the model predictions by investigating the extent
to which deliberate variations in input parameters affect opti-
mal master pool size, efficiency, and PPV. Second, as noted
above, contamination of individual specimens (prior to pool-
ing) can undermine pooling-related gains in accuracy and ef-
ficiency, and it is not comprehensively addressed in this paper.
Interference or inhibition of NAAT by biological material or
additives (e.g., heparin) from multiple specimens is an impor-
tant consideration as well (12, 20, 26, 38). Third, we did not
consider higher-order algorithms (four-stage hierarchical
TABLE 2. Recommended approach to pooling algorithm selectiona
Factor(s) Area(s) affected
Laboratory setting
Training, quality assurance, quality control ...........................................Feasibility of pooling for NAAT
Availability of robotics..............................................................................MAPS; acceptable algorithm complexity
No. of personnel ........................................................................................Possible frequency of NAAT runs (turnaround time)
Economic resources (assay budget, per assay cost) ..............................Minimal acceptable efficiency (maximum allowable test usage)
Available assay sensitivity.........................................................................MAPS; algorithm performance (efficiency, PPV)
Available assay specificity.........................................................................Algorithm performance
End-user requirements
Required turnaround time .......................................................................MAPS; maximum no. of pooling stages
Required accuracy for NAAT screen .....................................................Minimum acceptable PAS; minimum acceptable positive predictive value
Testing population
Anticipated throughput (rate of specimen arrival)...............................MAPS
No. of AHI anticipated; AHI prevalence ..............................................Algorithm performance
a Summary of important factors to be discussed in the planning process. Most of the factors listed serve to limit the available range of strategies a program can
consider. Information on the characteristics of the NAAT assay to be utilized and anticipated AHI prevalence can then be used to find relevant estimates of
performance for remaining candidate algorithms from Table 1 and Tables S1, S2, and S3 in the supplemental material. The ultimate algorithm choice will reflect a
balance of program needs and capacity.
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pools, cubic arrays) that might be possible using robotics. Pre-
liminary investigations indicate that the efficiency gained with
such algorithms tends to be relatively small compared to the
complexity and reduced turnaround time such strategies typi-
cally require (results not shown). Likewise, we did not consider
rectangular pooling algorithms (e.g., A2m with 8 rows and 12
columns). Last, while pooling may be applicable to a wide
variety of problems in medicine and public health beyond case
detection of AHI, many of the assumptions and parameters
included in this report will vary widely between diseases and
populations. Thus, these results should be generalized to other
settings cautiously.
While pooled testing will work accurately and efficiently in
combination with second-, third-, or fourth-generation
ELISAs, the choice of ELISA used for prescreening samples
can nonetheless alter the performance of pooling algorithms.
Newer “third-generation” (IgM-sensitive) and “fourth-genera-
tion” (combined antigen-antibody) ELISAs detect infections
earlier in seroconversion than older assays. When used to
prescreen samples for RNA pooling, these sensitive ELISAs
themselves may detect some cases of AHI. For this reason, the
apparent prevalence of AHI will be reduced when RNA pool-
ing is used in conjunction with a higher-generation ELISA.
The effects of using higher-generation ELISAs on the accuracy
and efficiency of pooling algorithms are the subject of current
investigation (for example, see reference 4).
Despite these limitations, the values of efficiency obtained
from these models can accurately predict real-world experi-
ences. For example, Pilcher et al. (28) observed an efficiency of
0.018 using a near-optimal D3 testing strategy of 90:10:1 with
a prevalence of 0.0002 and an assay specificity of 0.99. Given w
of 84 days and R of 0.52 log10 copies/ml/day, equation 1 indi-
cates that PAS is approximately 0.95. We can use Table 1 to
bound the efficiency of pooled testing at 0.013 on the lower end
(for a prevalence of 104) and 0.030 on the high end (for a
prevalence of 103), while the Web calculator estimates the
efficiency in the range of 0.015 to 0.017 (for square D3 pools of
100 and 81, respectively); all these estimates are consistent
with the experiences reported by Pilcher et al. (28). An effi-
ciency of approximately 0.02 means that approximately 2,200
NAAT kits were required to test 109,000 samples (27). At $50
per NAAT, optimized pooled testing saved over $5,000,000
compared to the costs of individual NAATs for the same pop-
ulation.
For AHI testing using specimen pooling, the tables and
algorithms presented here provide a resource for research and
public health laboratories interested in finding cases of AHI in
a wide variety of settings. Correct application of these algo-
rithms will in general substantially improve the efficiency and
PPV of case finding relative to individual testing.
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